It is plausible that combining chemotherapy with agents that inhibit CD44 on TMPs may reduce the potential for metastasis, and therefore can serve as a strategy to inhibit the possible risks of chemotherapy-induced metastasis in breast cancer. This evidence concerns the gene CD44 and breast carcinoma.